Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Update

by · The Markets Daily

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) saw a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,090,000 shares, a decline of 11.9% from the September 15th total of 4,640,000 shares. Based on an average daily trading volume, of 468,500 shares, the short-interest ratio is presently 8.7 days.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KNSA shares. Wedbush boosted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and an average price target of $33.60.

Check Out Our Latest Analysis on Kiniksa Pharmaceuticals

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,500 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares of the company’s stock, valued at $3,226,805.01. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sanj K. Patel sold 136,124 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the sale, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at $1,616,257.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 278,064 shares of company stock valued at $7,165,254 over the last quarter. Insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in KNSA. CWM LLC raised its holdings in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 1st quarter valued at approximately $71,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at approximately $100,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Kiniksa Pharmaceuticals by 88.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after purchasing an additional 3,611 shares during the period. Finally, Lynx1 Capital Management LP bought a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter valued at approximately $177,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Up 1.6 %

Kiniksa Pharmaceuticals stock opened at $27.06 on Wednesday. The business has a 50 day moving average price of $25.47 and a two-hundred day moving average price of $21.83. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 246.00 and a beta of 0.33. Kiniksa Pharmaceuticals has a 12 month low of $14.12 and a 12 month high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03. The firm had revenue of $108.30 million during the quarter, compared to analysts’ expectations of $90.60 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The company’s revenue for the quarter was up 51.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.02) EPS. On average, analysts expect that Kiniksa Pharmaceuticals will post -0.29 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

(Get Free Report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Featured Articles